Dr. Boccia describes the components of the bioT3 platform and its clinical utility in identifying tumor type and actionable targets for therapy.
Related Items
VBCC - September 2015, Vol 6, No 8 published on September 17, 2015 in Interview with the Innovators
VBCC - Media Library published on April 14, 2015 in Interview with the Innovators
VBCC - Media Library published on April 14, 2015 in Interview with the Innovators
VBCC - Media Library published on April 14, 2015 in Interview with the Innovators
VBCC - Media Library published on April 14, 2015 in Interview with the Innovators
VBCC - Media Library published on April 14, 2015 in Interview with the Innovators
VBCC - Media Library published on January 13, 2015 in Interview with the Innovators
VBCC - Media Library published on January 13, 2015 in Interview with the Innovators
VBCC - Media Library published on January 13, 2015 in Interview with the Innovators
Last modified: July 27, 2015